相关实验视频
Updated: Jan 10, 2026

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
22.2K
帕金森病中的视网膜结构变化:GBA1相关和异常病例之间的PRNFL厚度差异
Giacomo Portaro1, Michelangelo Giacomelli2, Sara Grisanti3
1Neurology Unit, Neuromotor and Rehabilitation Department, AUSL-IRCCS of Reggio Emilia, Italy.
Parkinsonism & related disorders
|November 29, 2025
概括
患有GBA1突变的帕金森病 (PD) 患者表现出比没有GBA1突变的患者更厚的视网膜神经纤维层 (RNFL). 在非突变的PD中,视网膜厚度与认知和运动功能相关.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 遗传学 是一个遗传学.
背景情况:
- 视网膜结构变化是帕金森病 (PD) 中神经退行症的潜在生物标志物.
- 在PD患者中观察到视网膜神经纤维层 (pRNFL) 厚度的减少.
- 关于视网膜结构的异常性PD和GBA1-相关PD (GBA-PD) 之间的差异尚未得到充分研究.
研究的目的:
- 为了研究GBA-PD和非突变PD (NM-PD) 之间的pRNFL厚度差异.
- 探索视网膜厚度与不同PD基因型中的临床变量之间的关联.
主要方法:
- 在59名PD患者 (32名GBA-PD,27名NM-PD) 的观察性研究中.
- 临床评估包括MoCA,MDS-UPDRS和霍恩-雅尔.
- 谱域OCT测量了6个部门和3个直径的pRNFL厚度.
主要成果:
- 与GBA-PD患者相比,NM-PD患者的时间pRNFL部门明显较薄.
- 在NM-PD中,较薄的上角pRNFL与MoCA得分相关,鼻下角pRNFL与MDS-UPDRS部分-IV相关.
- 在GBA-PD中没有发现PRNFL厚度和临床变量之间的显著关联.
结论:
- 在GBA-PD和NM-PD之间存在明显的视网膜厚度模式,表明不同的病理生理机制.
- 在NM-PD中,特定部门的pRNFL厚度与认知障碍和运动并发症相关.
- 视网膜成像可以提供关于基因型特异性神经退行和PD的临床表现的见解.
更多相关视频
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
11.0K
08:33Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
8.6K
相关概念视频
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K